AUS
NZ
UK
CA
USA
IND
Atomo Diagnostics Limited (ASX:AT1), an Australian manufacturer specialising in rapid diagnostic test devices, has announced it will hold its Q4 FY26 investor webinar on Friday, 24 July 2026. Managing Director and CEO John Kelly will deliver operational and financial updates to shareholders and market participants. The webinar offers investors a chance to engage directly with company leadership and submit questions via Atomo's dedicated Investor Hub platform.
Key Points
- Atomo Diagnostics Limited (ASX:AT1) will host its Q4 FY26 investor webinar on 24 July 2026 at 11am AEST
- CEO and Managing Director John Kelly will provide quarterly operational and financial updates to shareholders and institutional investors
- Pre-registration is mandatory to access the webinar through Atomo's investor portal
- Investors can submit questions and interact with management via the Investor Hub at https://investors.atomodiagnostics.com/auth/signup
Overview of Atomo Diagnostics and Its Role in Rapid Diagnostic Testing
Atomo Diagnostics Limited, headquartered in Leichhardt, New South Wales, is an Australian medical device company focused on manufacturing and supplying integrated rapid diagnostic test (RDT) devices globally. Operating within the point-of-care and at-home testing markets, Atomo targets rapidly expanding sectors in the global diagnostics industry. Its expertise in rapid diagnostic devices places it in a competitive yet growing market with rising demand from both developed and emerging healthcare systems.
The company’s patented technology streamlines testing processes, enhances user-friendliness, and boosts reliability across its rapid point-of-care and at-home testing products. This technological edge is vital in a market where accuracy and ease of use are critical for healthcare providers, laboratories, and consumers alike. Atomo’s commitment to innovation and commercialisation has helped it secure multiple international supply agreements and expand its global footprint.
Diverse Commercial Portfolio and Global Supply Agreements
Atomo has commercialised a broad range of products internationally, supported by supply agreements covering various diagnostic applications. Its portfolio includes rapid diagnostic devices for infectious diseases such as HIV and syphilis, liver health screening, viral versus bacterial differentiation, and female health testing. This diversified product mix spans multiple clinical areas and patient groups.
The company’s multi-channel go-to-market strategy, reflected in its wide-ranging supply agreements, aims to generate revenue across different segments and regions. By addressing both infectious disease diagnostics and general health screening, Atomo is positioned to meet acute diagnostic needs and routine preventative healthcare demands, potentially expanding its addressable market and customer base.
Q4 FY26 Investor Webinar as Part of Ongoing Shareholder Engagement
The upcoming Q4 FY26 investor webinar forms part of Atomo’s regular quarterly communication schedule. Hosting webinars after each financial quarter underscores the company’s dedication to transparent, consistent engagement with investors. This approach keeps shareholders informed about operational developments, financial results, and strategic initiatives on a predictable timeline.
Scheduled for late July 2026, shortly after the 30 June 2026 fiscal year-end, the webinar will likely cover both full-year FY26 results and Q4-specific updates. CEO John Kelly’s leadership in hosting the event highlights senior management’s commitment to open investor dialogue and shareholder relations, offering an opportunity for investors to seek clarifications on financial and operational matters.
Investor Hub Platform Facilitates Direct Investor Interaction
Atomo’s dedicated Investor Hub, accessible at https://investors.atomodiagnostics.com/auth/signup, enables investors to submit questions and provide feedback related to company announcements and developments. Shareholders are encouraged to use this platform for inquiries about the quarterly webinar and other investor topics. This digital tool represents a modern, asynchronous communication channel complementing scheduled live events.
Pre-registration through the Investor Hub helps Atomo gauge investor interest, manage webinar attendance, and tailor communications to participants. Allowing question submissions ahead of the webinar enables management to prepare thorough responses, enhancing the quality of investor engagement during the live presentation.
CEO John Kelly to Lead Investor Communications
John Kelly, Atomo Diagnostics’ Managing Director and CEO, will lead the Q4 FY26 investor webinar on 24 July 2026. His involvement reflects the importance of the quarterly update and senior leadership’s active engagement with shareholders. As the company’s chief executive, Kelly is responsible for conveying strategic direction, operational progress, and financial outcomes to the investment community.
Contact details for John Kelly and a dedicated investor queries email ([email protected]) have been provided, facilitating clear communication channels. This dual-contact system allows investors to direct strategic questions to the CEO while routing general inquiries through investor relations, ensuring efficient and organized correspondence.
Webinar Participation Details for Investors
The Q4 FY26 investor webinar will take place online on Friday, 24 July 2026, at 11am Australian Eastern Standard Time (AEST). Investors must pre-register to attend via the company’s investor portal, where they will receive access details and supporting materials ahead of the event.
The timing is convenient for Australian investors, though international participants may need to adjust for time zone differences. The online format removes geographic barriers, enabling broad shareholder participation. Pre-registration also ensures orderly event management and accurate attendance tracking, consistent with best practices for listed company investor presentations.
Patented Technology Drives Atomo’s Competitive Advantage
Atomo’s rapid diagnostic device portfolio is distinguished by patented technology that simplifies testing, improves usability, and enhances reliability compared to competitors. This technological differentiation is crucial in point-of-care and at-home testing, where ease of use, rapid results, and accuracy influence adoption by healthcare providers, laboratories, and consumers.
The company’s focus on user-friendly design reduces training needs, minimizes errors, and promotes patient compliance, especially important for at-home tests conducted by untrained users. Enhanced reliability ensures consistent, accurate results across diverse testing environments, reinforcing Atomo’s value proposition to healthcare stakeholders and distribution partners.
Global Market Reach and International Commercial Presence
Atomo Diagnostics operates internationally, supplying rapid diagnostic test devices across multiple global markets. The company has secured supply agreements with healthcare providers, laboratories, and distributors worldwide, demonstrating regulatory expertise and distribution capabilities across varied healthcare systems.
Serving developed regions like North America, Europe, and Asia-Pacific, as well as emerging markets with limited laboratory infrastructure, Atomo pursues growth beyond Australia. Its success in navigating regulatory and procurement complexities highlights its operational strength as an Australian-headquartered medical device company with a global footprint.
Investor Engagement and Future Communication Opportunities
The Q4 FY26 investor webinar offers shareholders a timely opportunity to gain insights into Atomo’s operational and financial status. Investors are encouraged to pre-register and submit questions via the Investor Hub to maximize engagement during the presentation. The platform will continue to support ongoing investor communications beyond this event.
Following the webinar, Atomo will maintain its quarterly reporting cadence, providing regular updates and engagement opportunities. Contact details for CEO John Kelly and the investor relations email facilitate continuous dialogue between scheduled events. Investors seeking to stay informed should subscribe to company announcements and ensure their contact information is up to date with the company’s share registry to receive future webinar invitations and updates.
